Shitalben Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9933114/publications.pdf

Version: 2024-02-01

567281 526287 1,174 30 15 27 citations h-index g-index papers 31 31 31 1394 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo- \hat{l}^2 -lactamase-producing enterobacterales. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115674.	1.8	8
2	Optimizing aminoglycoside selection for KPC-producing <i>Klebsiella pneumoniae</i> with the aminoglycoside-modifying enzyme (AME) gene <i>aac(6')-lb</i> . Journal of Antimicrobial Chemotherapy, 2021, 76, 671-679.	3.0	9
3	Extracts of Anogeissus leiocarpus and Dillenia indica Inhibit the Growth of MCF-7 Breast Cancer and COV434 Granulosa Tumor Cells by Inducing Apoptosis and Autophagy. Current Bioactive Compounds, 2021, 17, .	0.5	O
4	Transcriptomic analysis reveals that combinations of vitamins A, D2, and D3 have synergistic effects in HCT-116 colon cancer cells by altering the expression of genes involved in multiple canonical pathways including apoptosis, regulation of the Functional Foods in Health and Disease, 2021, 11, 154.	0.6	2
5	A randomized, openâ€label pharmacokinetic trial of tacrolimus extendedâ€release dosing in obese de novo kidney transplant recipients. Clinical Transplantation, 2019, 33, e13640.	1.6	4
6	Combinations of vitamins A, D2 and D3 have synergistic effects in gastric and colon cancer cells. Functional Foods in Health and Disease, 2019, 9, 749.	0.6	0
7	Isolation and identification of three new chromones from the leaves of <i>Pimenta dioica</i> with cytotoxic, oestrogenic and anti-oestrogenic effects. Pharmaceutical Biology, 2018, 56, 235-244.	2.9	10
8	Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. Journal of Cardiac Failure, 2016, 22, 692-699.	1.7	13
9	Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. Translational Psychiatry, 2016, 6, e739-e739.	4.8	53
10	Factors influencing pharmacokinetics of warfarin in African–Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics, 2015, 16, 217-225.	1.3	14
11	The mediating effect of prefrontal asymmetry on the relationship between the <i>COMT</i> Val ¹⁵⁸ Met SNP and trait consummatory positive affect. Cognition and Emotion, 2015, 29, 867-881.	2.0	14
12	Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. Psychopharmacology, 2015, 232, 145-154.	3.1	45
13	Pyrosequencing of the CYP2C9 -1766T>C polymorphism as a means of detecting the CYP2C9*8 allele. Pharmacogenomics, 2014, 15, 1717-1722.	1.3	3
14	Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 345-355.	3.2	19
15	Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenomics Journal, 2014, 14, 223-228.	2.0	59
16	Epithelial Sodium Channel Genotype Is Associated with Elevated Potassium among Patients with Heart Failure Taking a Mineralocorticoid Receptor Antagonist. Journal of Cardiac Failure, 2013, 19, S56.	1.7	0
17	VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thrombosis and Haemostasis, 2013, 109, 1045-1050.	3.4	24
18	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet, The, 2013, 382, 790-796.	13.7	237

#	Article	IF	CITATION
19	A Pharmacogenetics Service Experience for Pharmacy Students, Residents, and Fellows. American Journal of Pharmaceutical Education, 2013, 77, 175.	2.1	17
20	Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) and Genetic Ancestry with Atrial Fibrillation and Serum Aldosterone in African Americans with Heart Failure. PLoS ONE, 2013, 8, e71268.	2.5	14
21	Effect of <i>NQO1</i> and <i>CYP4F2</i> genotypes on warfarin dose requirements in Hispanic–Americans and African–Americans. Pharmacogenomics, 2012, 13, 1925-1935.	1.3	59
22	Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism. Clinical Pharmacology and Therapeutics, 2012, 91, 660-665.	4.7	83
23	Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction. Psychiatry Research, 2012, 199, 74-76.	3.3	16
24	Pharmacogenomics of Warfarin dose requirements in Hispanicsa~†. Blood Cells, Molecules, and Diseases, 2011, 46, 147-150.	1.4	36
25	The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans. Clinical Pharmacology and Therapeutics, 2011, 89, 408-415.	4.7	100
26	Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans. Clinical Pharmacology and Therapeutics, 2010, 87, 459-464.	4.7	186
27	A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans. Clinical Pharmacology and Therapeutics, 2010, 87, 445-451.	4.7	85
28	Predictors of unstable anticoagulation in African Americans. Journal of Thrombosis and Thrombolysis, 2009, 27, 430-437.	2.1	23
29	The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. European Journal of Clinical Pharmacology, 2009, 65, 651-658.	1.9	25
30	Cytochrome P450 2C9 mediated metabolism in people with and without cancer. International Journal of Clinical Pharmacology and Therapeutics, 2008, 46, 365-374.	0.6	16